Clinical Research Article

Genome-wide Association Study of Lipid Traits in Youth With Type 2 Diabetes

Nicola Santoro,1,2,* Ling Chen,3,* Jennifer Todd,4 Jasmin Divers,5 Amy S. Shah,6 Samuel S. Gidding,7 Brian Burke,8 Morey Haymond,9 Leslie Lange,10 Santica Marcovina,11 Jason Flannick,12,13 Sonia Caprio,1 Jose C. Florez,3,13,14 and Shylaja Srinivasan15

1Division of Pediatric Endocrinology, Yale School of Medicine, New Haven, CT, USA; 2Department of Medicine and Health Sciences “V. Tiberio,” University of Molise, Campobasso, Italy; 3Center for Genomic Medicine and Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA; 4Division of Pediatric Endocrinology, University of Vermont, Burlington, VT, USA; 5Division of Health Services Research, NYU Long Island School of Medicine, Mineola, NY, USA; 6Cincinnati Children’s Hospital Medical Center & The University of Cincinnati, Cincinnati, OH, USA; 7Geisinger, Danville, PA; 8The George Washington University, Washington, DC, USA; 9Division of Pediatric Endocrinology, Baylor College of Medicine, Houston, TX, USA; 10Department of Medicine, University of Colorado, Denver, CO, USA; 11Department of Medicine, University of Washington, Seattle, WA, USA; 12Department of Pediatrics, Boston Children’s Hospital, Boston, MA, USA; 13Programs in Metabolism and Medical & Population Genetics, Broad Institute of Harvard & Massachusetts Institute of Technology, Cambridge, MA, USA; and 14Department of Medicine, Harvard Medical School, Boston, MA, USA; 15Division of Pediatric Endocrinology, University of California at San Francisco, San Francisco, CA, USA

ORCID numbers: 0000-0001-6437-4173 (N. Santoro); 0000-0002-7523-5053 (S. Caprio); 0000-0002-8049-6370 (S. Srinivasan).

*Equal contributions.

Received: 3 June 2021; Editorial Decision: 16 August 2021; First Published Online: 18 August 2021; Corrected and Typeset: 23 September 2021.

Abstract

Context: Dyslipidemia is highly prevalent in youth with type 2 diabetes (T2D), yet the pathogenic components of dyslipidemia in youth with T2D are poorly understood.

Objective: To evaluate the genetic determinants of lipid traits in youth with T2D through a genome-wide association study.

Design, Participants, and Main Outcome Measures: We genotyped 206,928 variants and imputed 17,642,824 variants in 1076 youth (mean age 15.0 ± 2.48 years) with T2D from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) and SEARCH for Diabetes in Youth (SEARCH) studies as part of the Progress in Diabetes Genetics in Youth (ProDiGY) consortium. We performed association testing for triglyceride and low-density lipoprotein cholesterol and high-density lipoprotein cholesterol (HDL-c) concentrations adjusted for the genetic relationship matrix within each substudy followed by meta-analyses for each trait.
Results: We identified a novel association between a deletion on chromosome 3 (3:67817380_AT/A_Deletion:RP11-B1N13.1) and triglyceride levels at genome-wide level of significance ($P = 2.3 \times 10^{-8}$) with each risk allele increasing triglycerides by 20%. We also identified a genome-wide significant signal at rs247617 ($P = 5.1 \times 10^{-9}$) between HERFUD1 and CETP associated with HDL-c, with carriers of 1 copy of the risk allele having twice higher HDL-c.

Conclusions: Our genetic analyses of lipid traits in youth with T2D have identified 1 novel and 1 previously known locus. Additional studies are needed to further characterize the genetic architecture of dyslipidemia in youth with T2D.

Key Words: type 2 diabetes, youth, dyslipidemia, genetics, triglycerides, LDL-c, HDL-c

Over the last 2 decades, type 2 diabetes (T2D) in youth has emerged as a complication of early-onset obesity, affecting about 0.46 per 1000 youth [1]. Pediatric T2D usually manifests during puberty when puberty-related insulin resistance exacerbates obesity-related insulin resistance [2]. Dyslipidemia, which is both a comorbidity and a complication, is highly prevalent in youth with T2D [3]. However, the pathogenic components of dyslipidemia in youth with T2D are poorly understood. Similar to adults, glycemic control and duration of T2D are key contributors to dyslipidemia in youth [3]. Interestingly, not all youth with T2D develop dyslipidemia, even if obese.

The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study showed that elevated plasma concentrations of triglycerides ≥ 150 mg/dL were present in 21% of participants, low-density lipoprotein cholesterol (LDL-c) plasma concentrations ≥ 130 mg/dL were present in 4.5% of participants and high-density lipoprotein cholesterol (HDL-c) plasma concentrations ≤50 mg/dL in males and 40 mg/dL in females were present in 80% participants with newly diagnosed T2D at study enrollment [4]. Similarly, data from SEARCH for Diabetes in Youth (SEARCH) in 2001 and 2002 showed the high prevalence of dyslipidemia in youth with T2D with 24% with triglyceride levels ≥ 150 mg/dL, 15% with LDL-c levels ≥ 130 mg/dL, and 24% with total cholesterol levels ≥ 200 mg/dL [5].

Lipid traits including plasma levels of cholesterol, triglycerides, and lipoproteins are complex traits, whose variation is estimated to be determined by the interplay of genetic and environmental factors [6]. Previous genome-wide association studies (GWAS) in large populations of adults have discovered greater than 150 genetic variants associated with lipid traits [7]. These adult studies have also included small cohorts of children, but, to date, the contribution of genetic variants to dyslipidemia in youth with T2D remains unknown. The objective of this study is to discover the genetic determinants of lipids traits specifically in the context of T2D. To uncover the genetic underpinnings of dyslipidemia in youth with T2D, we performed a GWAS of lipid traits in a group of 1076 obese youth with T2D in the Progress in Diabetes Genetics in Youth (ProDiGY) consortium, composed of participants originally enrolled in 2 different pediatric studies: the TODAY study [8] and the SEARCH study [9].

Materials and Methods

Description of Participants

ProDiGY includes data from over 3000 cases with youth-onset T2D and 6000 diabetes-free adult controls. The cohort with diabetes includes 449 youth from the TODAY study, over 2000 youth with T2D from the TODAY ancillary genetics study, and 468 youth with T2D from SEARCH. The study also accesses data from over 10 000 adult cases and 10 000 controls from T2D-GENES [10]. This analysis included the subset of cases with lipid data, collected when the participants were enrolled: 539 participants from TODAY and 537 participants from SEARCH.

The TODAY and SEARCH studies are described in detail elsewhere [11,12]. TODAY and SEARCH protocols were approved by the institutional review boards of each participating institution. Participants provided written informed parental consent and child assent, including consent and assent specifically for genetic testing.

Lipid Measurements

In both TODAY and SEARCH studies, lipid analyses were performed in the same central laboratory using Roche reagents on a Roche Modular P autoanalyzer (Roche Diagnostics, Indianapolis, IN, USA) with methods standardized to the Centers for Disease Control and Prevention Reference Methods [13]. HDL-c was measured after precipitation of apolipoprotein B-containing particles with dextran sulfate Mg2+. LDL-c was calculated using the
Friedewald equation [14], except if plasma triglyceride concentrations were >400 mg/dL, in which case lipoprotein analyses were performed after ultracentrifugation using the Lipid Research Clinic Beta Quantification procedure. The TODAY study protocol defined lipid goals as LDL-c < 100mg/dL and triglycerides < 150 mg/dL. If lipid levels were outside the target range, initial therapy consisted of dietary counseling. If LDL-c remained ≥130 mg/dL or if triglyceride values remained 300–599 mg/dL after 6 months of dietary counseling and diabetes management, pharmacological treatment with atorvastatin was initiated. If triglycerides were ≥600 mg/dL, fibrate therapy could be initiated at the discretion of the treating physician [11]. Participants in SEARCH had lipid management based on the discretion of their treating physician. Participants on lipid-lowering medications were not removed from these analyses.

Genotyping, Imputation, and Quality Control

ProDiGY samples were genotyped on the Infinium array by the Genetic Analysis Platform at the Broad Institute. The directly genotyped data were called by using the Autocall algorithm. All quality control steps were run in PLINK2 and R-3.4. Imputation was done using the Michigan Imputation Server against the 1000G Phase 3 v5 panel as the reference. After cleaning, 17 642 824 single nucleotide polymorphisms remained.

Statistical Analysis

Baseline lipid traits including LDL-c, HDL-c, and triglycerides were analyzed with a generalized linear mixed model (EMMAX) by using the Efficient and Parallelizable Association Container Toolbox (EPACTS) within the TODAY and SEARCH cohorts. Meta-analyses were run by METAL to combine the results from each cohort. The TODAY study protocol defined lipid goals as LDL-c < 100mg/dL and triglycerides < 150 mg/dL. If lipid levels were outside the target range, initial therapy consisted of dietary counseling. If LDL-c remained ≥130 mg/dL or if triglyceride values remained 300–599 mg/dL after 6 months of dietary counseling and diabetes management, pharmacological treatment with atorvastatin was initiated. If triglycerides were ≥600 mg/dL, fibrate therapy could be initiated at the discretion of the treating physician [11]. Participants in SEARCH had lipid management based on the discretion of their treating physician. Participants on lipid-lowering medications were not removed from these analyses.

Table 1. Clinical characteristics of the study groups

|                      | TODAY (n = 539) | SEARCH (n = 498) | Total (n = 1037) |
|----------------------|----------------|-----------------|-----------------|
| Age (years)          | 14.4 ± 2.01    | 15.6 ± 2.80     | 15.0 ± 2.48     |
| Sex (girls), %       | 64.0           | 60.9            | 62.6            |
| BMI z-score          | 2.22 ± 0.47    | 2.12 ± 0.66     | 2.17 ± 0.57     |
| Triglycerides (mg/dL)| 115.6 ± 80.71  | 159.1 ± 170.2   | 136.6 ± 133.2   |
| LDL-c (mg/dL)        | 83.9 ± 24.4    | 105.4 ± 31.82   | 94.2 ± 30.2     |
| HDL-c (mg/dL)        | 38.7 ± 8.59    | 41.2 ± 10.4     | 39.9 ± 9.5      |
| Lipid medication, %  | 1              | 2.6             | 1.7             |
| Glycemic parameters  |                |                 |                 |
| Glucose (mg/dL)      | 110.4 ± 23.8   | 156.4 ± 82.2    | 132.4 ± 63.6    |
| Insulin (uU/mL)      | 30.9 ± 22.3    | 32.5 ± 34.1     | 31.4 ± 26.2     |
| HbA1c, %             | 6.01 ± 0.75    | 7.53 ± 2.32     | 6.73 ± 1.84     |
| T2D duration (years) | 0.7 ± 0.5      | 1.5 ± 1.5       | 1.1 ± 1.2       |

The table shows the baseline clinical characteristics of the participants enrolled in SEARCH and TODAY separately and combined. Data are shown as mean and SD. Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; SEARCH, SEARCH for Diabetes in Youth; T2D, type 2 diabetes mellitus; TODAY, Treatment Options for Type 2 Diabetes in Adolescents and Youth; TRIG, triglycerides.

Results

The clinical characteristics of the study populations at baseline are shown in Table 1. Mean age of the participants with T2D was 15.0 ± 2.48 years, 62.6% were female, mean body mass index z-score was 2.17 ± 0.57, and mean hemoglobin A1c was 6.73 ± 1.84%. We discovered genome-wide significant signals for HDL-c and triglycerides. The GWAS for HDL-c showed a genome-wide significant association at rs247617 in chromosome 16 (P = 5.1 × 10⁻⁹) (Fig. 1). rs247617 represents a cytosine-to-adenine change in a regulatory region (CTCF binding site) of chromosome 16 in close proximity to the CETP gene. The minor allele frequencies of rs247617 in each ethnicity and study are shown in Table 2. Characteristics of the study group according to the rs247617 genotypes are shown in Table 3. Participants carrying 1 copy of the minor rs247617 allele had 1.1 times higher HDL-c plasma levels as compared to participants homozygous for the common allele (P = 0.01). We also discovered a genome-wide significant association for triglycerides at rs148323096 (P = 2.3 × 10⁻⁸) on chromosome 3 characterized by a deletion of 1 T (ancestral TT) in the last intron of the SUCLG2-AS1 gene. Frequency of the T deletion in each study by ethnicity is shown in Table 4. rs148323096 was associated with triglycerides in both TODAY (P = 0.03) and SEARCH (P = 0.03) studies. Characteristics of the study group according to the rs148323096 genotypes are shown in Table 5. Participants with deletion of 1 T allele had 2.19 times (P = 2.26 × 10⁻⁸) higher triglyceride levels compared to participants without the deletion. The GWAS for LDL-c did not reveal any genome-wide significant associations.

Discussion

To our knowledge, this is the first GWAS of lipid traits performed in a cohort of youth with T2D. Despite the relatively small sample size for a GWAS, we were able to replicate
a previously discovered association between rs247617 in CETP and HDL-c and discover a new association between rs148323096 near the SUCLG2-AS1 gene and plasma triglyceride concentrations. The contributions of adiposity, insulin resistance, and dysglycemia are difficult to disentangle in the pathogenesis of dyslipidemia in T2D. Our results shed light on the genetic contribution of dyslipidemia specifically in the context of T2D while still accounting for the role of dysglycemia and adiposity.

Participants carrying 1 copy of the minor rs247617 allele had higher plasma HDL-c levels as compared to participants homozygous for the common allele. This observation is consistent with observations in larger studies in adults [15,16]. The CETP gene product is the cholesteryl ester transfer protein, whose function is to transfer cholesteryl esters from HDL-c to apolipoprotein B–containing particles [17]. rs247617 in the CETP gene is characterized by a cytosine-to-adenine substitution in the regulatory region of the CETP gene and the presence of the minor allele is predicted to reduce the expression of the CETP gene causing a rise in HDL-c levels [18]. This variant has been associated with lower concentrations of triglycerides in very low-density lipoprotein, intermediate low-density lipoprotein, and HDL-c [19]. Additionally, observational data in 3 adult population-based cohorts totaling 616 incident cases and 13,564 controls during 8 years of follow-up showed that genetic variation in CETP was associated with reduced cardiovascular disease risk [19]. Overall, data from adults

Figure 1. This figure shows the Manhattan plot for the association with high-density lipoprotein cholesterol (HDL-C) (A) and triglycerides (B). (C) and (D) show the Q-Q plots for HDL-c and triglycerides, respectively.
indicate that the association between rs247617 and CETP results in beneficial alterations in lipid levels.

rs148323096 is an intronic indel variant in SUCLG2-AS1 that is an antisense RNA gene of SUCLG2. This is the first study showing an association between the rs148323096 and plasma triglyceride concentrations. It should be noted that the association results were in the same direction and were nominally significant in both TODAY and SEARCH individually, further validating our finding. rs14832096 is in almost complete linkage disequilibrium with 9 variants in SUCLG2-AS1, but all of them are intronic, and given the lack of functional studies, their consequences on gene expression or function are difficult to predict. The SUCLG2 gene encodes a GTP-specific beta subunit of succinyl-coenzyme A (CoA) synthetase, an enzyme that catalyzes the formation of succinyl-CoA.

SUCLG2-AS1 belongs to the group of long noncoding RNAs that are believed to regulate the transcription of the gene [20]. Although functional studies or Expression Quantitative Trait Loci for this variant are missing, one could speculate that rs148323096 in SUCLG2-AS1 may negatively affect the regulation of succinate-CoA synthetase by reducing its expression in the liver. Reduced hepatic expression of succinate-CoA ligase could cause an accumulation of citrate, a substrate for acetyl-CoA, which in turn can fuel de novo hepatic lipogenesis causing an increase of triglyceride synthesis and production. Kibbey et al demonstrated that succinyl-CoA synthetase might modulate glucose-induced insulin resistance at the mitochondrial level (Table 3).

### Table 2. Minor allele frequencies and Hardy-Weinberg equilibrium of rs247617 genotype in CETP gene by ancestral group

|          | TODAY | SEARCH | Total |
|----------|-------|--------|-------|
|          | C/C   | A/C    | A/A   | C/C   | A/C    | A/A   | C/C | A/C | A/A | C/C | A/C | A/A | C/C | A/C | A/A |
| n        | 287   | 214    | 38    | 253   | 200    | 45    | 540  | 414  | 83  |
| MAF EUR  | 0.27  | 0.31   | 0.29  | 0.28  | 0.28   | 0.28  | 0.27 | 0.27 | 0.23|
| MAF AFR  | 0.28  | 0.28   | 0.28  | 0.27  | 0.30   | 0.29  | 0.21 | 0.14 | 0.18|
| MAF AMR  | 0.27  | 0.30   | 0.29  | 0.27  | 0.30   | 0.29  | 0.21 | 0.14 | 0.18|
| MAF EAS  | 0.21  | 0.14   | 0.18  | 0.21  | 0.14   | 0.18  | 0.21 | 0.14 | 0.18|
| MAF SAS  | N/A   | N/A    | N/A   | 0.14  | 0.27   | 0.23  | 0.14 | 0.27 | 0.23|
| MAF Others| 0.14  | 0.27   | 0.23  | 0.14  | 0.27   | 0.23  | 0.14 | 0.27 | 0.23|
| HWE P-value |       |        |       |       |        |       |       |       |    |
| EUR      | 0.79  | 0.44   | 0.45  | 0.42  | 0.73   | 0.77  | 0.76 | 0.66 | 0.42|
| AFR      | 0.42  | 0.73   | 0.77  | 0.78  | 0.90   | 0.76  | 0.47 | 0.66 | 0.42|
| AMR      | 0.47  | 0.66   | 0.42  | 0.47  | 0.66   | 0.42  | 0.47 | 0.66 | 0.42|
| EAS      | N/A   | N/A    | N/A   | 0.14  | 0.27   | 0.23  | 0.14 | 0.27 | 0.23|
| SAS      | N/A   | N/A    | N/A   | 0.14  | 0.27   | 0.23  | 0.14 | 0.27 | 0.23|
| Others   | 0.53  | 0.77   | 0.71  | 0.53  | 0.77   | 0.71  | 0.53 | 0.77 | 0.71|

Abbreviations: A, effect allele; AFR, African American; AMR, Hispanic; C, non-effect allele; EAS, East Asian; EUR, European; HWE, Hardy-Weinberg equilibrium; N/A, too few participants to compute; SAS, South Asian.
secretion through GTP formation in the mitochondria [21]. Therefore, it would be interesting to test glucose-induced insulin responses in participants carrying the risk allele to assess whether this variant may play any role in the development of prediabetes and T2D in youth. A strength of our study is that this is the first large-scale study of dyslipidemia in youth with T2D. However, despite this, the sample size remains relatively small size for a GWAS limiting the power to detect more variants. Also, while our study was multiethnic, our numbers were too small for meaningful analyses separately by ancestral group. It should also be noted that participants enrolled in the SEARCH study tended to have higher lipid, glucose, and hemoglobin A1c concentrations than youth enrolled in the TODAY study (Table 1). This may be due to the different enrollment criteria of the 2 studies and because TODAY was a clinical trial while SEARCH is an observational study. Additionally, while the objective of our study was to evaluate the genetics of dyslipidemia specifically in youth with T2D, it would be important to replicate our findings in a both lean and obese pediatric cohorts without diabetes, well matched for age and sex, and divided into lean and similarly increased body mass index groups.

In conclusion, our genetic analyses of lipid traits in youth with T2D uncovered a novel association with triglycerides and a known association with HDL-c. While this study offers the first glimpse of the genetics of lipid traits in youth with T2D, increased sample size and diversity and additional functional studies are needed to further understand the genetic components of dyslipidemia in youth with T2D.

**Acknowledgments**

SEARCH for Diabetes in Youth: The SEARCH for Diabetes in Youth Study is indebted to the many youth and their families, and their health care providers, whose participation made this study possible.

---

**Table 4. Minor allele frequency and Hardy-Weinberg equilibrium of rs148323096 genotype in SUCLG2-AS1 by ancestral group**

|          | TODAY                     | SEARCH                    | Total         |
|----------|---------------------------|---------------------------|---------------|
|          | AT/AT                     | A/AT                      | AT/AT         | A/AT  |
| n        | 521                       | 18                        | 479           | 19    | 1000 | 37   |
| MAF      |                           |                           |               |       |
| EUR      | 0.048                     | 0.037                     | 0.043         |       |
| AFR      | 0.0027                    | 0.0049                    | 0.0038        |       |
| AMR      | 0.0093                    | 0.024                     | 0.015         |       |
| EAS      | 0                         | 0.071                     | 0.036         |       |
| SAS      | 0.25                      | N/A                       | 0.25          |       |
| Others   | 0.036                     | 0.016                     | 0.022         |       |
| HWE P-value |                           |                           |               |       |
| EUR      | 0.59                      | 0.69                      | 0.51          |       |
| AFR      | 0.97                      | 0.94                      | 0.94          |       |
| AMR      | 0.89                      | 0.77                      | 0.77          |       |
| EAS      | N/A                       | 0.84                      | 0.89          |       |
| SAS      | 0.64                      | N/A                       | 0.64          |       |
| Others   | 0.89                      | 0.93                      | 0.88          |       |

**Table 5. Clinical characteristics of the study groups by rs148323096 genotype**

|          | TODAY                     | SEARCH                    | TOTAL         |
|----------|---------------------------|---------------------------|---------------|
|          | AT/AT                     | A/AT                      | AT/AT         | A/AT  |
| n        | 521                       | 18                        | 479           | 19    | 1000 | 37   |
| Age      | 14.4 ± 2.01               | 14.3 ± 1.87               | 15.6 ± 2.77   | 16.1 ± 2.43 | 15.0 ± 2.48 | 15.2 ± 2.3 |
| Sex (girls %) | 64.3                      | 55.5                      | 61.3          | 57.8  | 62.9 | 56.7 |
| BMI z-score | 2.22 ± 0.47               | 2.22 ± 0.47               | 2.12 ± 0.66   | 2.01 ± 0.65 | 2.17 ± 0.57 | 2.11 ± 0.57 |
| Lipid traits |                            |                           |               |       |
| TRIG (mg/dL) | 111.9 ± 70.5              | 221.8 ± 203.6*             | 152.3 ± 140.7 | 350.4 ± 484.7** | 131.0 ± 111.2 | 287.8 ± 375.9*** |
| LDL-c (mg/dL) | 83.78 ± 24.2              | 90.4 ± 31.2                | 105.9 ± 32.2  | 99.7 ± 23.9 | 94.2 ± 30.3 | 95.4 ± 27.7 |
| HDL-c (mg/dL) | 38.9 ± 8.64               | 34.9 ± 6.03                | 41.45 ± 10.25 | 35.2 ± 10.7 | 40.01 ± 9.52 | 35.1 ± 8.73 |
| Lipid medication (%) | 1%                        | 0%                        | 2.7%          | 0%    | 1.8% | 0%   |
| Glycemic parameters |                            |                           |               |       |
| Glucose (mg/dL) | 110.6 ± 23.9              | 106 ± 22.2                | 156.7 ± 82.3  | 150.8 ± 82.5 | 132.5 ± 63.6 | 129.6 ± 65.1 |
| Insulin (uU/mL) | 30.9 ± 22.5               | 30.4 ± 17.5               | 32.1 ± 33.8   | 40.5 ± 41.1 | 31.3 ± 26.1 | 34.2 ± 28.2 |
| HbA1c % | 6.01 ± 0.75               | 5.94 ± 0.68               | 7.53 ± 2.31   | 6.73 ± 2.04 | 6.74 ± 1.85 | 6.34 ± 1.57 |

The table shows the baseline clinical characteristics of the participants by rs148323096 in SEARCH and TODAY separately and combined. Data are shown as mean and SD. *P = 0.03; **P = 0.03; ***P = 2.26 × 10⁻⁸.

Abbreviations: A/AT, risk bearing genotype with deletion of T; AT/AT, non-risk bearing genotype; BMI, body mass index; HbA1c, hemoglobin A1c; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; SEARCH, SEARCH for Diabetes in Youth; TODAY, Treatment Options for Type 2 Diabetes in Adolescents and Youth; TRIG, triglycerides.
SEARCH 3/4: The authors wish to acknowledge the involvement of the Kaiser Permanente Southern California’s Clinical Research Center (funded by Kaiser Foundation Health Plan and supported in part by the Southern California Permanente Medical Group); the South Carolina Clinical & Translational Research Institute, at the Medical University of South Carolina, NIH/National Center for Advancing Translational Sciences (NCATS) grant number UL1 TR000062, UL1 TR001450; Seattle Children’s Hospital and the University of Washington, NIH/NCATS grant number UL1 TR00423; University of Colorado Pediatric Clinical and Translational Research Center, NIH/NCATS grant number UL1 TR000154; the Barbara Davis Center at the University of Colorado at Denver (DERC NIH grant number P30 DK57516); the University of Cincinnati, NIH/NCATS grant number UL1 TR000077, UL1 TR001425; and the Children with Medical Handicaps program managed by the Ohio Department of Health. This study includes data provided by the Ohio Department of Health, which should not be considered an endorsement of this study or its conclusions. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Institute of Diabetes and Digestive and Kidney Diseases.

Author Contributions

L.C. conducted the analysis and edited and approved the manuscript. S.S. and N.S. assisted in forming the analyses plan, interpretation of data, manuscript writing, and edited and approved the manuscript. J.T., J.D., A.S., S.G., B.B., M.H., L.L., S.M., J.F., and S.C. assisted in forming the analyses plan, interpretation of data, and edited and approved the manuscript. J.C.F supervised analyses and interpretation of data and edited and approved the manuscript. S.S. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the results.

Financial Support

S.S is supported by NIH grant 1K23DK120932.

Disclosure Summary

The authors do not have any disclosures to report.

Additional Information

Correspondence: Shylaja Srinivasan, 550 16th Street, 4th Floor, San Francisco, CA 94158, USA. Email: shylaja.srinivasan@ucsf.edu.

Data Availability: The data sets analyzed in the current study are publicly available in dbGap (dbGaP Study Accession: phs001511.v1.p1, https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001511.v1.p1). No applicable resources were generated or analyzed during the current study.

References

1. Dabelea D, Mayer-Davis EJ, Saydah S, et al; SEARCH for Diabetes in Youth Study. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311(17):1778-1786.
2. Amiel SA, Caprio S, Sherwin RS, Plewe G, Haymond MW, Tamborlane WV. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab. 1991;72(2):277-282.
3. Petitti DB, Imperatore G, Palla SL, et al; SEARCH for Diabetes in Youth Study Group. Serum lipids and glucose control: the SEARCH for Diabetes in Youth study. Arch Pediatr Adolesc Med. 2007;161(2):159-165.
4. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1758-1764.
5. Kershnan AK, Daniels SR, Imperatore G, et al. Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study. J Pediatr. 2006;149(3):314-319.
6. Goode EL, Cherry SS, Christian JC, Jarvik GP, de Andrade M. Heritability of longitudinal measures of body mass index and lipid and lipoprotein levels in aging twins. Twin Res Hum Genet. 2007;10(5):703-711.
7. Kuivenhoven JA, Hegele RA. Mining the genome for lipid genes. Biochim Biophys Acta. 2014;1842(10):1993-2009.
8. Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247-2256.
9. Dabelea D, Mayer-Davis EJ, Saydah S, et al; SEARCH for Diabetes in Youth Study. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311(17):1778-1786.
10. Flannick J, Mercader JM, Fuchsberger C, et al; Broad Genomics Platform; DiscovEHR Collaboration; CHARGE; LuCamp; ProDiGY; GoT2D; ESP; SIGMA-T2D; T2D-GENES; AMP-T2D-GENES. Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. Nature. 2019;570(7759):71-76.
11. Zeitler P, Epstein L, Greys M, et al. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes. 2007;8:74-87.
12. SEARCH Study Group. SEARCH for diabetes in youth: a multicenter study of the prevalence, incidence and classification of diabetes mellitus in youth. Controlled Clin Trials. 2004;25:458-471.
13. TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1758-1764.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
15. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41(1):56-65.
16. Lanktree MB, Anand SS, Yusuf S, Hegele RA; SHARE Investigators. Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. J Lipid Res. 2009;50(7):1487-1496.
17. Boekholdt SM, Kuivenhoven JA, Hovingh GK, Jukema JW, Kastelein JJ, van Tol A. CETP gene variation: relation to lipid parameters and cardiovascular risk. *Curr Opin Lipidol.* 2004;15(4):393-398.

18. Dachet C, Poirier O, Cambien F, Chapman J, Rouis M. New functional promoter polymorphism, CETP-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. *Arterioscler Thromb Vasc Biol.* 2000;20(2):507-515.

19. Kettunen J, Holmes MV, Allara E, et al. Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition. *PloS Biol.* 2019;17(12):e3000572.

20. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. *Nat Rev Genet.* 2009;10(3):155-159.

21. Kibbey RG, Pongratz RL, Romanelli AJ, Wollheim CB, Cline GW, Shulman GI. Mitochondrial GTP regulates glucose-stimulated insulin secretion. *Cell Metab.* 2007;5(4):253-264.